10 Biotechnology Stocks to Buy Now

by Portfolio Grader | November 28, 2012 6:00 pm

This week, 10 Biotechnology stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
This week, Celsion (NASDAQ:CLSN[2]) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celsion is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. In Portfolio Grader’s specific subcategory of Earnings Revisions, CLSN also gets an A. The stock price has risen 81.4% over the past month, better than the 0.6% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of CLSN stock[3].
Infinity Pharmaceuticals’ (NASDAQ:INFI[4]) ratings are looking better this week, moving up to a A from last week’s B. Infinity Pharmaceuticals researches and develops cancer drugs. Investors have pushed the stock price up 11.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INFI stock[5].
Galena Biopharma (NASDAQ:GALE[6]) shows solid improvement this week. The company’s rating rises from a B to a A. Galena Biopharma is a biopharmaceuticals company that develops late-stage oncology drugs. For more information, get Portfolio Grader’s complete analysis of GALE stock[7].
Pluristem Therapeutics’ (NASDAQ:PSTI[8]) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Pluristem Therapeutics develops Messenchymal stem cell production technology and commercializes cell therapy products. For more information, get Portfolio Grader’s complete analysis of PSTI stock[9].
Cytori Therapeutics (NASDAQ:CYTX[10]) is seeing ratings go up from a C last week to a B this week. Cytori Therapeutics develops, manufactures and sells medical products to enable the practice of regenerative medicine. For more information, get Portfolio Grader’s complete analysis of CYTX stock[11].
Amicus Therapeutics (NASDAQ:FOLD[12]) shows solid improvement this week. The company’s rating rises from a C to a B. Amicus Therapeutics is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. For more information, get Portfolio Grader’s complete analysis of FOLD stock[13].
Gentium (NASDAQ:GENT[14]) earns a A this week, jumping up from last week’s grade of B. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. For more information, get Portfolio Grader’s complete analysis of GENT stock[15].
GTx Inc. (NASDAQ:GTXI[16]) boosts its rating from a C to a B this week. GTx discovers, develops, and commercializes therapeutics primarily related to the treatment of serious men’s health conditions. For more information, get Portfolio Grader’s complete analysis of GTXI stock[17].
This week, QLT Inc.’s (NASDAQ:QLTI[18]) ratings are up from a C last week to a B. QLT develops and commercializes pharmaceutical products for use in photodynamic therapy, the use of light activated drugs to treat disease. The stock has a trailing PE Ratio of 8.60. For more information, get Portfolio Grader’s complete analysis of QLTI stock[19].
NPS Pharmaceuticals (NASDAQ:NPSP[20]) gets a higher grade this week, advancing from a B last week to a A. NPS Pharmaceuticals is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs. For more information, get Portfolio Grader’s complete analysis of NPSP stock[21].

Louis Navellier’s proprietary Portfolio Grader[22] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[23].